Research proved that dapagliflozin could significantly reduce the phosphorylation levels of JNK and p38 MAPK in mouse cardiomyocytes, improved cardiac hypertrophy and myocardial interstitial fibrosis and delayed the pathological progression of ventricular systolic dysfunction.40 Here, MAPK8 is linked to cardiac hypertrophy.